OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 


Archiving: full-text archived in CLOCKSS.

Publication Speed (median values for papers published in 2022): Submission to First Decision: 6 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Allogeneic Stem Cell Transplantation

Submission Deadline: April 30, 2022 (Open) Submit Now

Guest Editor

Martin Guimond, PhD

Associate Professor, Department of Microbiology, Infection, and Immunology, University of Montreal, Montreal, Quebec, Canada; Research Center, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

Website | E-Mail

Research Interests: T Lymphocytes; immunomodulation; allogeneic stem cell transplatation; stem cell transplantation; graft-versus-host disease; immunology

About this topic

In 1980, the New England Journal of Medicine published the first successful unrelated bone marrow transplantation to treat acute leukemia. Since then, the field of stem cell transplantation has evolved considerably. Today, allogeneic-SCT remains the only curative treatment for several patients with high risk refractory hematologic cancers. Recently, clinical trials were developed to evaluate the use of Allogeneic Stem Cell transplantation to treat/cure solid tumors. This Special Issue will cover new developments in the field of Allogeneic Stem Cell Transplantation including new procedures in Allogeneic Stem cell Transplantation, conditioning regiments, stem cell source, strategies to reduce/control acute or chronic graft-versus-host disease (T cell depletion, mesenchymal stem cells, suicide genes…), modulation of graft-versus leukemia (cytokines, CAR-T cells), management of infectious complications, strategies to improve immune reconstitution, in vitro and in vivo studies, animal models, and clinical trials on Allogeneic Stem Cell Transplantation. Original research papers, mini and full reviews and commentaries are all welcome. There is no restriction on the length of the manuscripts. Peer-review is commissioned immediately upon receipt of the manuscript.


Open Access Original Research

The P2X7 Receptor Antagonist AZ10606120 Does Not Alter Graft-Versus-Host Disease Development and Increases Serum Human Interferon-γ in a Humanized Mouse Model

Received: 06 June 2022;  Published: 06 September 2022;  doi: 10.21926/obm.transplant.2203166


Allogeneic hematopoietic stem cell transplantation is a curative therapy for hematological malignancies, but its efficacy is limited by graft-versus-host disease (GVHD). This life-threatening disorder develops when donor (graft) immune cells cause inflammatory damage to recipient (host) tissues. The immune cell receptor channel P2X7 and its [...]
Open Access Editorial

The Role of Cytochrome P450 2J2 in Cancer: Cell Protector, Therapeutic Target, or Prognostic Marker?

Received: 08 July 2022;  Published: 27 July 2022;  doi: 10.21926/obm.transplant.2203163


Cytochrome P450 2J2 (CYP2J2) is one of the recently discovered enzymes that is involved in the metabolism of several drugs. It is mainly an extrahepatic enzyme which can, to some extent, explain some the drugs’ side effects such as cyclophosphamide (Cy). Cyclophosphamide is an alkylating agent that is commonly used in conditioning prior [...]
Open Access Research Article

Umbilical Cord Blood as an Alternate Donor Sources for High Risk Elderly Patients Undergoing Allogeneic Stem Cell Transplantation for Hematological Malignancies

Received: 04 November 2020;  Published: 07 February 2021;  doi: 10.21926/obm.transplant.2101136


Allogeneic stem cell transplantation remains the only curative option for many hematological malignancies. Umbilical cord blood (UCB) is an alternate donor source with potentially increased morbidity in elderly patients. We evaluated outcomes in alternate donor sources, prior to the initiation of haploidentical transplantation at our instituti [...]
Open Access Original Research

“Real World” Australian Experience of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adults with Severe Aplastic Anaemia.

Received: 23 June 2020;  Published: 23 October 2020;  doi: 10.21926/obm.transplant.2004121


Acquired Severe Aplastic Anaemia (SAA) is a rare bone marrow failure syndrome, for which allogeneic haematopoietic stem cell transplant (HSCT) is a proven curative therapy. Despite excellent outcomes for matched sibling SAA recipients in terms of engraftment and survival, HSCT remains highly challenging in older matched-unrelated-donor (MUD [...]